Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.
Several other equities analysts have also recently weighed in on the stock. Wedbush reiterated a “neutral” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, February 12th. Zacks Investment Research cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Piper Jaffray Companies set a $25.00 price objective on shares of Sangamo Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Finally, Barclays assumed coverage on shares of Sangamo Therapeutics in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $18.83.
Sangamo Therapeutics (NASDAQ:SGMO) opened at $23.30 on Friday. Sangamo Therapeutics has a one year low of $3.65 and a one year high of $23.75. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1,970.00, a P/E ratio of -33.77 and a beta of 2.87.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. The firm had revenue of $11.81 million for the quarter, compared to analysts’ expectations of $10.37 million. During the same quarter in the prior year, the business earned ($0.27) EPS. The business’s quarterly revenue was up 333.0% on a year-over-year basis. research analysts expect that Sangamo Therapeutics will post -0.73 earnings per share for the current fiscal year.
In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $18.49, for a total transaction of $92,450.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Steven J. Mento sold 11,520 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $20.59, for a total transaction of $237,196.80. Following the sale, the director now owns 5,000 shares in the company, valued at approximately $102,950. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,953 shares of company stock worth $1,544,843. 5.50% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SGMO. Alexandria Capital LLC bought a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $15,179,000. State Street Corp raised its stake in Sangamo Therapeutics by 51.6% during the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after acquiring an additional 636,296 shares during the period. Vanguard Group Inc. raised its stake in Sangamo Therapeutics by 12.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock worth $30,551,000 after acquiring an additional 384,031 shares during the period. American Century Companies Inc. bought a new stake in Sangamo Therapeutics during the 3rd quarter worth approximately $5,145,000. Finally, Tocqueville Asset Management L.P. raised its stake in Sangamo Therapeutics by 105.0% during the 4th quarter. Tocqueville Asset Management L.P. now owns 665,890 shares of the biopharmaceutical company’s stock worth $10,921,000 after acquiring an additional 341,075 shares during the period. Institutional investors own 64.22% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/02/17/sangamo-therapeutics-sgmo-rating-increased-to-strong-buy-at-bidaskclub.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.